drugset / Trial / NCT04644107

Expanded Access for Marizomib

NCT04644107 ↗

Expanded access No longer available Celgene Corporation

Summary

This is an expanded access program (EAP) for eligible participants designed to provide access to Marizomib.

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Background Marizomib Small molecule — Intravenous

Indications